Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ALB | P02768 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.52 |
| ▸ | ADCY5 | O95622 | 6/20 | 0.48 |
| ▸ | AHCY | P23526 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7654778 | 1.00 | NR1I2 (0.67) | NR1I2ALBPDE4DABCB1ADCY5 | |
| SCHEMBL31454794 | 1.00 | NR1I2 (0.67) | NR1I2ALBPDE4DABCB1ADCY5 | |
| SCHEMBL13789990 | 1.00 | NR1I2 (0.67) | NR1I2ALBPDE4DABCB1ADCY5 | |
| SCHEMBL6764237 | 1.00 | NR1I2 (0.67) | NR1I2ALBPDE4DABCB1ADCY5 | |
| SCHEMBL31454816 | 1.00 | NR1I2 (0.67) | NR1I2ALBPDE4DABCB1ADCY5 | |
| SCHEMBL6694128 | 1.00 | NR1I2 (0.67) | NR1I2ALBPDE4DABCB1ADCY5 | |
| SCHEMBL14048997 | 1.00 | NR1I2 (0.67) | NR1I2ALBPDE4DABCB1ADCY5 | |
| SCHEMBL7099022 | 1.00 | NR1I2 (0.67) | NR1I2ALBPDE4DABCB1ADCY5 | |
| Hydrochloric Acid SCHEMBL6897280 | 0.99 | NR1I2 (0.66) | NR1I2ALBPDE4DABCB1ADCY5 | |
| Hydrochloric Acid SCHEMBL6897283 | 0.99 | NR1I2 (0.66) | NR1I2ALBPDE4DABCB1ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448402-B2 | REDUCTION OF 2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE USING METAL HYRIDE | LONZA AG (CH) | 2002-09-10 | — | — | US | claimed |
| CN-112512529-B | Cyclopentenepurine derivative or salt thereof | 富士胶片株式会社 | 2024-06-18 | — | — | CN | disclosed |
| US-20230111132-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| EP-4081254-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021133742-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133742-A1 | STABILIZATION OF MHC COMPLEXES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210155644-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-05-27 | — | — | US | disclosed |
| CN-112512529-A | Cyclopentene purine derivatives or salts thereof | 富士胶片株式会社 | 2021-03-16 | — | — | CN | disclosed |
| US-20190000853-A1 | ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS | UNIV LIVERPOOL (GB) | 2019-01-03 | — | — | US | disclosed |
| US-20190000853-A1 | ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS | UNIV LIVERPOOL (GB) | 2019-01-03 | — | — | US | disclosed |
| US-5034394-A | Therapeutic nucleosides | BURROUGHS WELLCOME CO. (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0434450-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| WO-1991000282-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-01-10 | — | — | WO | disclosed |
| US-4950758-A | ANTIVIRAL AND ANTITUMOR AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1990-08-21 | — | — | US | disclosed |
| US-4931559-A | VIRICIDES, ANTITUMOR AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0366385-A1 | Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-05-02 | — | — | EP | disclosed |
| US-4916224-A | VIRICIDES FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0361831-A1 | Antiviral nucleoside combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
| EP-0349242-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
| EP-0346132-A1 | Pharmaceutical products | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000853-A1 | ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS | MAVS, TYMP, SAMHD1 | NR1I2 2110/4885ALB 4515/4885PDE4D 460/4885 |
| US-20230111132-A1 | STABILIZATION OF MHC COMPLEXES | MICA, CD74, HLA-DRB1 | NR1I2 2104/4885ALB 356/4885PDE4D 4838/4885 |
| US-20210155644-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, NOX1 | NR1I2 1724/4885ALB 4355/4885PDE4D 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.